The FDA approved fam-trastuzumab derextecan-nki (Enhertu; Daiichi Sankyo, Inc), a HER2-directed antibody-drug conjugate (ADC), in combination with pertuzumab as a first-line treatment for patients ...

For patients living with HER2-positive metastatic breast cancer, the recent FDA approval of trastuzumab deruxtecan (brand ...

The FDA approved trastuzumab deruxtecan (T-DXd; Enhertu) in combination with pertuzumab (Perjeta) for the first-line ...

FDA approval moves trastuzumab deruxtecan in combination with pertuzumab into frontline treatment of unresectable or ...

Patients should be selected for treatment with Enhertu in combination with pertuzumab based on confirmed HER2-positive status or HER2 gene amplification (IHC 3+ or ISH+).

AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) in combination with pertuzumab has been approved in the US for the 1st-line treatment of adult patients with unresectable or ...

The U.S. Food and Drug Administration (FDA) has approved Enhertu (fam-trastuzumab deruxtecan-nxki) in combination with ...

Please provide your email address to receive an email when new articles are posted on . Trastuzumab deruxtecan improved invasive DFS by 53% vs. T-DM1 for patients with residual disease after ...

The 5 most-read breast cancer articles on AJMC.com this year included FDA approvals, emerging therapies for metastatic breast ...

Please provide your email address to receive an email when new articles are posted on . Trastuzumab deruxtecan reduced risk for disease progression or death compared with trastuzumab emtansine among ...

TOKYO & MUNICH--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) today announced that the European Medicines Agency (EMA) has validated the Type II Variation application for trastuzumab deruxtecan as ...

Trastuzumab emtansine is the current standard treatment for patients with human epidermal growth factor receptor 2 (HER2)–positive metastatic breast cancer whose disease progresses after treatment ...